The development of a mammalian brain is a complex and long-lasting process. Not surprisingly, preterm birth is the leading cause of death in newborns and children. Advances in perinatal care reduced mortality, but morbidity still represents a major burden. New therapeutic approaches are thus desperately needed. Given that mesenchymal stem/stromal cells (MSCs) emerged as a promising candidate for cell therapy, we transplanted MSCs derived from the Wharton's Jelly (WJ-MSCs) to reduce the burden of immature brain injury in a murine animal model. WJ-MSCs transplantation resulted in protective activity characterized by reduced myelin loss and astroglial activation. WJ-MSCs improved locomotor behavior as well. To address the underlying mechanisms, we tested the key regulators of responses to DNA-damaging agents, such as cyclic AMP-dependent protein kinase/calcium-dependent protein kinase (PKA/PKC), cyclin-dependent kinase (CDK), ataxia-telangiectasia-mutated/ATM- and Rad3-related (ATM/ATR) substrates, protein kinase B (Akt), and 14-3-3 binding protein partners. We characterized WJ-MSCs using a specific profiler polymerase chain reaction array. We provide evidence that WJ-MSCs target pivotal regulators of the cell fate such as CDK/14-3-3/Akt signaling. We identified leukemia inhibitory factor as a potential candidate of WJ-MSCs' induced modifications as well. We hypothesize that WJ-MSCs may exert adaptive responses depending on the type of injury they are facing, making them prominent candidates for cell therapy in perinatal injuries.
Get full access to this article
View all access options for this article.
References
1.
PhillipsJB, AbbotP and RokasA. (2015). Is preterm birth a human-specific syndrome?. Evol Med Public Health, 2015:136–148.
2.
LiuL, OzaS, HoganD, PerinJ, RudanI, LawnJE, CousensS, MathersC and BlackRE. (2015). Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet, 385:430–440.
3.
NumeratoD, FattoreG, TediosiF, ZaniniR, PeltolaM, BanksH, MihaliczaP, LehtonenL, SvereusS, et al. (2015). Mortality and length of stay of very low birth weight and very preterm infants: a EuroHOPE study. PLoS One, 10:e0131685.
4.
SchaafJM, MolBW, Abu-HannaA and RavelliAC. (2011). Trends in preterm birth: singleton and multiple pregnancies in the Netherlands, 2000–2007. BJOG, 118:1196–1204.
5.
HamrickSE, MillerSP, LeonardC, GliddenDV, GoldsteinR, RamaswamyV, PiecuchR and FerrieroDM. (2004). Trends in severe brain injury and neurodevelopmental outcome in premature newborn infants: the role of cystic periventricular leukomalacia. J Pediatr, 145:593–599.
6.
MarretS, Marchand-MartinL, PicaudJC, HascoetJM, ArnaudC, RozeJC, TruffertP, LarroqueB, KaminskiM, AncelPY and GroupES. (2013). Brain injury in very preterm children and neurosensory and cognitive disabilities during childhood: the EPIPAGE cohort study. PLoS One, 8:e62683.
7.
LoboN, YangB, RizviM and MaD. (2013). Hypothermia and xenon: novel noble guardians in hypoxic-ischemic encephalopathy?. J Neurosci Res, 91:473–478.
8.
TitomanlioL, KavelaarsA, DalousJ, ManiS, El GhouzziV, HeijnenC, BaudO and GressensP. (2011). Stem cell therapy for neonatal brain injury: perspectives and challenges. Ann Neurol, 70:698–712.
9.
HigginsRD, RajuT, EdwardsAD, AzzopardiDV, BoseCL, ClarkRH, FerrieroDM, GuilletR, GunnAJ, et al. (2011). Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD workshop. J Pediatr, 159:851–858e1.
10.
CahillAG, StoutMJ and CaugheyAB. (2010). Intrapartum magnesium for prevention of cerebral palsy: continuing controversy?. Curr Opin Obstet Gynecol, 22:122–127.
11.
MuellerM, WolfsTG, SchoeberleinA, GavilanesAW, SurbekD and KramerBW. (2016). Mesenchymal stem/stromal cells-a key mediator for regeneration after perinatal morbidity?. Mol Cell Pediatr, 3:6.
12.
MesserliM, WagnerA, SagerR, MuellerM, BaumannM, SurbekDV and SchoeberleinA. (2013). Stem cells from umbilical cord Wharton's jelly from preterm birth have neuroglial differentiation potential. Reprod Sci, 20:1455–1464.
13.
Castillo-MelendezM, YawnoT, JenkinG and MillerSL. (2013). Stem cell therapy to protect and repair the developing brain: a review of mechanisms of action of cord blood and amnion epithelial derived cells. Front Neurosci, 7:194.
14.
VolpeJJ. (2009). Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol, 8:110–124.
15.
HassR, KasperC, BohmS and JacobsR. (2011). Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 9:12.
16.
LeeJW, FangX, KrasnodembskayaA, HowardJP and MatthayMA. (2011). Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells, 29:913–919.
17.
PhillipsAW, JohnstonMV and FatemiA. (2013). The potential for cell-based therapy in perinatal brain injuries. Transl Stroke Res, 4:137–148.
18.
BackSA and RosenbergPA. (2014). Pathophysiology of glia in perinatal white matter injury. Glia, 62:1790–1815.
19.
OsugaH, OsugaS, WangF, FetniR, HoganMJ, SlackRS, HakimAM, IkedaJE and ParkDS. (2000). Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci U S A, 97:10254–10259.
20.
Miras-PortugalMT, Gomez-VillafuertesR, GualixJ, Diaz-HernandezJI, ArtalejoAR, OrtegaF, DelicadoEG and Perez-SenR. (2015). Nucleotides in neuroregeneration and neuroprotection. Neuropharmacology, 104:243–254.
21.
MuellerM, SchoeberleinA, ZhouJ, Joerger-MesserliM, OppligerB, ReinhartU, BordeyA, SurbekD, BarneaE, HuangY and PaidasM. (2015). PreImplantation factor bolsters neuroprotection via modulating protein kinase A and protein kinase C signaling. Cell Death Differ, 22:2078–2086.
22.
KimHH, AbdelmohsenK and GorospeM. (2010). Regulation of HuR by DNA damage response kinases. J Nucleic Acids, 2010:pii:981487.
23.
MengS, ArbitT, VeeriahS, MellinghoffIK, FangF, VivancoI, RohleD and ChanTA. (2009). 14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell Cycle, 8:2238–2246.
24.
HermekingH and BenzingerA. (2006). 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol, 16:183–192.
25.
XuN, LaoY, ZhangY and GillespieDA. (2012). Akt: a double-edged sword in cell proliferation and genome stability. J Oncol, 2012:951724.
26.
VerdaguerE, Susana GdeA, ClemensA, PallasM and CaminsA. (2007). Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. Biomed Pharmacother, 61:390–399.
27.
FooteM and ZhouY. (2012). 14-3-3 proteins in neurological disorders. Int J Biochem Mol Biol, 3:152–164.
28.
ShimadaT, FournierAE and YamagataK. (2013). Neuroprotective function of 14-3-3 proteins in neurodegeneration. Biomed Res Int, 2013:564534.
29.
SchoeberleinA, MuellerM, ReinhartU, SagerR, MesserliM and SurbekDV. (2011). Homing of placenta-derived mesenchymal stem cells after perinatal intracerebral transplantation in a rat model. Am J Obstet Gynecol, 205:277.e1–e6.
30.
MuellerM, ZhouJ, YangL, GaoY, WuF, SchoeberleinA, SurbekD, BarneaER, PaidasM and HuangY. (2014). PreImplantation factor promotes neuroprotection by targeting microRNA let-7. Proc Natl Acad Sci U S A, 111:13882–13887.
31.
MeierC, MiddelanisJ, WasielewskiB, NeuhoffS, Roth-HaererA, GantertM, DinseHR, DermietzelR and JensenA. (2006). Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res, 59:244–249.
32.
SchneiderCA, RasbandWS and EliceiriKW. (2012). NIH image to ImageJ: 25 years of image analysis. Nat Methods, 9:671–675.
33.
RamachandraR, SubramanianT. (2011). Atlas of the Neonatal Rat Brain. Boca Raton, FL, CRC Press.
34.
SizonenkoSV, KissJZ, InderT, GluckmanPD and WilliamsCE. (2005). Distinctive neuropathologic alterations in the deep layers of the parietal cortex after moderate ischemic-hypoxic injury in the P3 immature rat brain. Pediatr Res, 57:865–872.
35.
OppligerB, Jorger-MesserliM, MuellerM, ReinhartU, SchneiderP, SurbekD and SchoeberleinA. (2016). Intranasal delivery of umbilical cord-derived mesenchymal stem cells preserves myelination in perinatal brain damage. Stem Cells Dev, 25:1234–1242.
36.
DonegaV, van VelthovenCT, NijboerCH, van BelF, KasMJ, KavelaarsA and HeijnenCJ. (2013). Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PLoS One, 8:e51253.
37.
JellemaRK, Lima PassosV, ZwanenburgA, OpheldersDR, De MunterS, VanderlochtJ, GermeraadWT, KuypersE, CollinsJJ, et al. (2013). Cerebral inflammation and mobilization of the peripheral immune system following global hypoxia-ischemia in preterm sheep. J Neuroinflammation, 10:13.
38.
SizonenkoSV, SirimanneE, MayallY, GluckmanPD, InderT and WilliamsC. (2003). Selective cortical alteration after hypoxic-ischemic injury in the very immature rat brain. Pediatr Res, 54:263–269.
39.
Joerger-MesserliMS, MarxC, OppligerB, MuellerM, SurbekDV and SchoeberleinA. (2016). Mesenchymal stem cells from Wharton's jelly and amniotic fluid. Best Pract Res Clin Obstet Gynaecol, 31:30–44.
40.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
41.
van VelthovenCT, KavelaarsA, van BelF and HeijnenCJ. (2011). Mesenchymal stem cell transplantation changes the gene expression profile of the neonatal ischemic brain. Brain Behav Immun, 25:1342–1348.
42.
LeeJA, KimBI, JoCH, ChoiCW, KimEK, KimHS, YoonKS and ChoiJH. (2010). Mesenchymal stem-cell transplantation for hypoxic-ischemic brain injury in neonatal rat model. Pediatr Res, 67:42–46.
43.
van VelthovenCT, KavelaarsA, van BelF and HeijnenCJ. (2010). Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res, 68:419–422.
44.
OrtinauC and NeilJ. (2014). The neuroanatomy of prematurity: normal brain development and the impact of preterm birth. Clin Anat.
45.
MisumiS, UedaY, NishigakiR, SuzukiM, IshidaA, JungCG and HidaH. (2016). Dysfunction in motor coordination in neonatal white matter injury model without apparent neuron loss. Cell Transplant, 25:1381–1393.
46.
FollettPL, RosenbergPA, VolpeJJ and JensenFE. (2000). NBQX attenuates excitotoxic injury in developing white matter. J Neurosci, 20:9235–9241.
47.
CraigA, Ling LuoN, BeardsleyDJ, Wingate-PearseN, WalkerDW, HohimerAR and BackSA. (2003). Quantitative analysis of perinatal rodent oligodendrocyte lineage progression and its correlation with human. Exp Neurol, 181:231–240.
48.
LiuY, SilversteinFS, SkoffR and BarksJD. (2002). Hypoxic-ischemic oligodendroglial injury in neonatal rat brain. Pediatr Res, 51:25–33.
49.
ManningSM, TalosDM, ZhouC, SelipDB, ParkHK, ParkCJ, VolpeJJ and JensenFE. (2008). NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J Neurosci, 28:6670–6678.
50.
McQuillenPS, SheldonRA, ShatzCJ and FerrieroDM. (2003). Selective vulnerability of subplate neurons after early neonatal hypoxia-ischemia. J Neurosci, 23:3308–3315.
51.
LeendersAG and ShengZH. (2005). Modulation of neurotransmitter release by the second messenger-activated protein kinases: implications for presynaptic plasticity. Pharmacol Ther, 105:69–84.
52.
LibienJ, SacktorTC and KassIS. (2005). Magnesium blocks the loss of protein kinase C, leads to a transient translocation of PKC(alpha) and PKC(epsilon), and improves recovery after anoxia in rat hippocampal slices. Brain Res Mol Brain Res, 136:104–111.
53.
OzgenH, KahyaN, de JongeJC, SmithGS, HarauzG, HoekstraD and BaronW. (2014). Regulation of cell proliferation by nucleocytoplasmic dynamics of postnatal and embryonic exon-II-containing MBP isoforms. Biochim Biophys Acta, 1843:517–530.
54.
KulkarniA and DasKC. (2008). Differential roles of ATR and ATM in p53, Chk1, and histone H2AX phosphorylation in response to hyperoxia: ATR-dependent ATM activation. Am J Physiol Lung Cell Mol Physiol, 294:L998–L1006.
55.
LiA, WangJ, WuM, ZhangX and ZhangH. (2015). The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway. Eur J Pharmacol, 747:71–87.
56.
JangSW, LiuX, FuH, ReesH, YepesM, LeveyA and YeK. (2009). Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons. J Biol Chem, 284:24512–24525.
57.
BradshawRA, PundavelaJ, BiarcJ, ChalkleyRJ, BurlingameAL and HondermarckH. (2015). NGF and ProNGF: regulation of neuronal and neoplastic responses through receptor signaling. Adv Biol Regul, 58:16–27.
58.
WangX, BalohRH, MilbrandtJ and GarciaKC. (2006). Structure of artemin complexed with its receptor GFRalpha3: convergent recognition of glial cell line-derived neurotrophic factors. Structure, 14:1083–1092.
59.
CarrascoE, WernerP and CasperD. (2008). Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress. Neurosci Lett, 441:44–49.
60.
YueX, WuL and HuW. (2015). The regulation of leukemia inhibitory factor. Cancer Cell Microenviron, 2:pii:e877.
61.
RoweDD, CollierLA, SeifertHA, ChapmanCB, LeonardoCC, WillingAE and PennypackerKR. (2014). Leukemia inhibitor factor promotes functional recovery and oligodendrocyte survival in rat models of focal ischemia. Eur J Neurosci, 40:3111–3119.
62.
DavisSM, CollierLA, LeonardoCC, SeifertHA, AjmoCTJr. and PennypackerKR. (2016). Leukemia inhibitory factor protects neurons from ischemic damage via upregulation of superoxide dismutase 3. Mol Neurobiol. [Epub ahead of print]; DOI:10.1007/s12035-015-9887-2.
63.
FanYY, ZhangJM, WangH, LiuXY and YangFH. (2013). Leukemia inhibitory factor inhibits the proliferation of primary rat astrocytes induced by oxygen-glucose deprivation. Acta Neurobiol Exp (Wars), 73:485–494.
64.
SlaetsH, DumontD, VanderlochtJ, NobenJP, LeprinceP, RobbenJ, HendriksJ, StinissenP and HellingsN. (2008). Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics, 8:1237–1247.
65.
LiuX, TsengSC, ZhangMC, ChenSY, TigheS, LuWJ and ZhuYT. (2015). LIF-JAK1-STAT3 signaling delays contact inhibition of human corneal endothelial cells. Cell Cycle, 14:1197–1206.
66.
FischbachMA, BluestoneJA and LimWA. (2013). Cell-based therapeutics: the next pillar of medicine. Sci Transl Med, 5:179ps7.
67.
MitsialisSA and KourembanasS. (2016). Stem cell-based therapies for the newborn lung and brain: possibilities and challenges. Semin Perinatol, 40:138–151.
68.
OuhazZ, Ba-M'hamedS, MitchellAS, ElidrissiA and BennisM. (2015). Behavioral and cognitive changes after early postnatal lesions of the rat mediodorsal thalamus. Behav Brain Res, 292:219–232.
69.
RossettiT, NichollsF and ModoM. (2016). Intracerebral cell implantation: preparation and characterization of cell suspensions. Cell Transplant, 25:645–664.
70.
ChenA, SiowB, BlamireAM, LakoM and ClowryGJ. (2010). Transplantation of magnetically labeled mesenchymal stem cells in a model of perinatal brain injury. Stem Cell Res, 5:255–266.
71.
KabadiSV and FadenAI. (2014). Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials. Neural Regen Res, 9:1578–1580.
72.
SeeWL, MillerJP, SquatritoM, HollandE, ReshMD and KoffA. (2010). Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas. Oncogene, 29:1720–1731.
73.
Cowper-SmithCD, AngerGJ, MagalE, NormanMH and RobertsonGS. (2008). Delayed administration of a potent cyclin dependent kinase and glycogen synthase kinase 3 beta inhibitor produces long-term neuroprotection in a hypoxia-ischemia model of brain injury. Neuroscience, 155:864–875.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
